A site has not gained productivity when AI completes a task in seconds but staff spend the next hour checking the answer, correcting it, documenting the review, and moving the result into another system.
That distinction matters as sponsors introduce more AI-enabled tools for patient matching, document management, data review, site initiation, feasibility, communication, and operational follow-up. Each tool may promise faster work, but sites experience the complete workflow, including every alert, handoff, correction, approval, and duplicate entry created around it.
Sites therefore need a meaningful voice in how clinical AI is selected, designed, introduced, and measured. Their involvement can help ensure the technology solves a real operational problem and reduces total workload rather than shifting it into a different part of the process.
Why Should Sites Be Involved Before an AI Tool Is Selected?
Sponsors and technology providers can see the task they want to improve. Sites can see everything surrounding that task.
A patient-matching tool may appear to reduce manual chart review, but coordinators know how potential matches are confirmed, who contacts the treating physician, when patients can be approached, and which information is usually missing. A document tool may classify files accurately while still creating extra work if staff must upload them manually, verify every field, and transfer the results into another system.
Early site input can reveal:
Where the workflow currently slows down
Which steps require repeated data entry
Which information is difficult to access
Where professional judgment is essential
Which exceptions occur frequently
Who has authority to act on an output
Which systems must exchange information
What additional review or documentation the tool may create
This insight helps sponsors evaluate whether AI addresses the real bottleneck. It can also prevent a technically successful implementation from becoming an operational disappointment.
What Should Sites Know About the AI They Are Expected to Use?
Sites should receive more than instructions for navigating a platform. They need a clear explanation of why the tool is being introduced and how it is expected to improve the work.
That communication should address:
The problem the tool is intended to solve
The tasks it will perform or support
The information it will access
The limitations of its outputs
The actions site staff remain responsible for
The level of review each output requires
How errors or concerns should be reported
How site feedback will be used
What success should look like for the site
This context helps staff understand how the tool fits into the study and why the change may be worthwhile. It also gives them a stronger basis for identifying when the technology is behaving differently from what was intended.
Communication should continue after launch. AI workflows may change as the model, data, study, or site configuration evolves. Sites need timely updates when those changes affect how they should interpret or review an output.
Different AI Tools Require Different Levels of Oversight
Clinical AI covers a wide range of activities, and the review requirements should reflect the risk and consequence of each use.
An AI tool that organizes meeting notes or routes routine documents may require limited review. A system that recommends a patient for screening, identifies a possible safety issue, interprets an eligibility criterion, or changes a controlled record requires stronger oversight from qualified staff.
A practical oversight framework can separate use cases into broad levels.
Lower-risk administrative support
These tools may classify documents, prepare meeting materials, summarize approved information, send reminders, or route tasks. Review can often focus on exceptions, sampling, or confirmation that the action was completed correctly.
Operational decision support
These systems may prioritize patient records, identify missing information, flag data inconsistencies, or recommend follow-up actions. Users need enough evidence to understand the recommendation and determine whether action is appropriate.
Patient-facing or regulated decisions
These applications may influence eligibility, safety assessment, clinical interpretation, informed consent, or critical study data. They require qualified human review, clear documentation, and defined accountability before consequential action is taken.
Treating every AI output as equally risky can create unnecessary work. Applying minimal review to every output can leave important decisions underprotected. The oversight model should match the use case, the available evidence, and the potential consequence of an error.
When Does Human Oversight Become Another Form of Site Burden?
Human oversight creates value when it applies judgment at a meaningful decision point. It becomes burdensome when staff are asked to reperform the work the AI was supposed to reduce.
This often happens when an output lacks supporting evidence, confidence indicators, or links to source information. Reviewers must then search several systems and reconstruct the result before they can decide whether it is correct.
The same problem appears when sites receive too many low-value alerts. If coordinators regularly dismiss poor matches, irrelevant warnings, or incomplete recommendations, the technology creates another queue instead of improving the workflow.
Sponsors should examine the full review process:
How long does it take to evaluate an output?
Can the reviewer see the supporting information immediately?
How often does the output require correction?
Does approval require extra documentation?
Must information be re-entered elsewhere?
Are alerts reaching someone who can act?
What happens when the AI is uncertain?
Can routine, low-risk results be managed through sampling or exception review?
Oversight costs should be included in the productivity calculation. A tool that saves ten hours of initial work but creates twelve hours of review, correction, and documentation has increased the site’s workload.
AI Should Fit the Site’s Existing Work
Sites differ in staffing, systems, patient populations, research experience, and internal approval processes. A workflow that succeeds at a large academic medical center may create problems for a community practice with fewer coordinators and less technical support.
AI implementation should begin with a clear view of how work currently moves through each type of site. Sponsors do not need to create a completely different product for every research center, but they should allow enough flexibility to reflect meaningful operational differences.
That may include:
Adjusting alert thresholds
Routing tasks to different roles
Integrating with local systems
Changing when recommendations appear
Limiting unnecessary notifications
Supporting different review pathways
Providing site-specific training
Allowing sites to prioritize studies or tasks
Configuration matters because timing and context often determine whether an AI output is useful. A strong recommendation delivered to the wrong person, in the wrong system, or after the relevant decision has passed creates little value.
How Can Sites Help Improve the Tool?
Every site interaction with an AI output produces useful feedback. A rejected recommendation, corrected classification, missed patient, irrelevant alert, or delayed action can reveal where the model or workflow needs improvement.
Sites should have a simple way to record:
Whether the output was useful
Why a recommendation was rejected
Which information was missing
Whether the alert arrived at the right time
How long review required
What action followed
Whether the issue recurred
How the workflow could improve
Collecting feedback is only the first step. Sponsors and vendors should show sites how that information affects the system. If coordinators repeatedly report the same poor matches or unnecessary alerts without visible improvement, they may stop providing feedback or disengage from the tool entirely.
Regular conversations can add context that structured data misses. Site staff may explain that an alert is technically correct but operationally useless, that a recommended action conflicts with local practice, or that a workflow works well except during high-volume periods.
These details help turn site feedback into practical product and process improvements.
What Should Training Cover?
Site training should focus on decisions and responsibilities rather than platform features alone.
Staff need to understand:
What the AI can and cannot do reliably
Which data sources support its outputs
How to interpret recommendations and uncertainty
What information should be verified
When human approval is required
Who is qualified to provide that approval
How to correct or reject an output
When and how to escalate a concern
How AI-assisted work should be documented
Where to get timely support
Training should use realistic site scenarios. Staff can practice reviewing a possible patient match, responding to an uncertain classification, handling a missing source record, or deciding whether an alert requires escalation.
Different roles may need different instruction. A coordinator reviewing matches, an investigator confirming clinical suitability, and a regulatory specialist managing documents do not interact with the same risks or decisions.
How Should Sponsors Measure Whether AI Reduced Site Burden?
Adoption alone does not prove that a tool improved the site experience. Sites may use required technology even when it makes their work harder.
Measurement should cover the complete workflow before and after implementation. Useful measures may include:
Total cycle time
Active staff time
Number of manual steps
Review and correction time
Duplicate data entry
Alert acceptance and dismissal rates
Number of systems staff must access
Time required to resolve exceptions
Errors or rework
Tasks completed per staff member
User confidence and satisfaction
Effects on enrollment, startup, or data quality
Sponsors should also look for burden that appears elsewhere. A tool may save coordinator time while creating more work for investigators, pharmacists, data staff, or regulatory teams.
Direct site feedback remains essential. Quantitative measures can show where work changed, while conversations with users explain whether that change was genuinely helpful.
What Does Meaningful Site Partnership Look Like?
Site participation should extend beyond a single advisory meeting held after the major decisions have already been made.
A stronger approach involves sites at several points:
Problem definition: Confirm that the proposed use case addresses a significant operational need.
Workflow design: Map how the tool will interact with existing roles, systems, and decisions.
Testing: Evaluate the system using realistic site scenarios and representative data.
Implementation: Provide role-specific training, support, and clear expectations.
Measurement: Track total workload, workflow outcomes, and user experience.
Improvement: Use site feedback to refine the technology and its operating model.
This type of partnership improves more than adoption. It helps sponsors understand whether the AI solves the intended problem under real operating conditions.
Sites should also be able to raise concerns without being viewed as resistant to innovation. Questions about added work, unclear data use, weak integration, or excessive review may identify genuine implementation risks.
Design AI Around the People Doing the Work
Clinical trial sites are expected to absorb growing protocol complexity, expanding data requirements, and an increasing number of technology platforms. AI may help reduce that pressure, but only when implementation begins with the realities of site work.
Sponsors and vendors should be able to explain what a tool improves, what it asks sites to do differently, and how much human review it requires. They should also measure whether the complete workflow became faster, easier, or more reliable after implementation.
Giving sites a voice strengthens those decisions. It helps ensure that AI reduces repetitive work, directs attention toward meaningful exceptions, and supports the people responsible for turning a protocol into a study that patients can actually join.
Continue the Conversation at SCOPE Summit Europe
AI-enabled site workflows, technology burden, sponsor-site collaboration, and practical implementation will be important areas of discussion at SCOPE Summit Europe. Leaders from across clinical research will explore how organizations can introduce new technology while supporting the sites and research teams expected to use it.
Learn more and register here.